Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kendall, S DiSean
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC	Recruiting	3	200	US	Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)	Shanghai Henlius Biotech	Extensive Stage Small Cell Lung Cancer	04/25	12/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia	Active, not recruiting	2	196	US	asciminib, ABL001	Novartis Pharmaceuticals	Chronic Myelogenous Leukemia - Chronic Phase	09/25	10/27
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma	Recruiting	1/2	70	US	Ivaltinostat, Capecitabine, Xeloda	CG Pharmaceuticals, Inc	Metastatic Pancreatic Adenocarcinoma	02/26	06/26